stockportfolio.pro
BMY vs PFE: Which Stock Is the Better Buy?
Bristol-Myers Squibb Company and Pfizer Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BMY vs PFE, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Bristol-Myers Squibb Company (BMY) | Pfizer Inc. (PFE) | |
|---|---|---|
| Market cap | $118.7B | $138.6B |
| Revenue (latest FY) | $48.19B | $62.58B |
| Net income (latest FY) | $7.05B | $7.77B |
| Revenue growth (5y CAGR) | 2.5% | 8.5% |
| Net margin | 14.6% | 12.4% |
| Return on equity | 38.2% | 9.0% |
| P/E ratio | 16.3 | 18.6 |
| Dividend yield | 4.3% | 7.1% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | Yes |
See the full BMY vs PFE breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BMY's full financials → Open PFE's full financials →Frequently asked questions
Which is bigger, BMY or PFE?
Pfizer Inc. is larger by market capitalization — $138.6B versus $118.7B.
Which grows faster, BMY or PFE?
Over the last five fiscal years, Pfizer Inc. grew revenue faster — 8.5%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.